Tirzepatide, a Dual GIP/GLP-1 Agonist, Potently Reduces HbA1c, Weight, and Cardiovascular Risk Factors in Type 2 Diabetes

Patients with Type 2 Diabetes Mellitus (T2DM) face a significantly elevated risk of cardiovascular disease (CVD), which remains a leading cause of morbidity and mortality. Current standard-of-care treatments, while effective in managing hyperglycemia, often fall short in comprehensively addressing the multifaceted metabolic dysfunctions, including obesity, dyslipidemia, and hypertension, that contribute to CVD progression. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists has marked a significant advance, offering both glycemic control and weight reduction. However, the dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors by compounds like tirzepatide presents a novel strategy to achieve even more profound metabolic improvements and potentially greater cardiovascular protection.

This review synthesizes findings from the phase III SURPASS clinical trial program, which investigated the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, or 15 mg weekly. The trials evaluated tirzepatide as monotherapy and add-on therapy in patients with type 2 diabetes mellitus, comparing it against placebo, basal insulin, semaglutide (1 mg), or dulaglutide (0.75 mg). The review summarizes the pharmacodynamics and pharmacokinetics of tirzepatide, and discusses its anticipated beneficial effects on the prevention and management of atherosclerosis and dyslipidemia based on the comprehensive metabolic improvements observed in the SURPASS trials.

The SURPASS trials consistently demonstrated that tirzepatide produced significant reductions in key metabolic parameters. Patients treated with tirzepatide achieved HbA1c reductions ranging from -1.87% to -2.58%, significantly outperforming comparators. Body weight reductions were also substantial, ranging from -6.2 kg to -12.9 kg, without increasing the risk of serious hypoglycemia. Beyond glycemic control and weight loss, tirzepatide also improved lipid parameters, including reductions in triglycerides and increases in HDL cholesterol, and lowered blood pressure. These improvements collectively suggest a strong potential for cardiovascular risk reduction. Most observed adverse events were mild gastrointestinal symptoms, with occurrence rates comparable to those associated with other GLP-1 receptor agonists like semaglutide (1 mg) or dulaglutide (0.75 mg).